Tuesday, November 17, 2026

AI Medical Service raises 8 billion yen in total! Accelerating the construction of a cloud platform for endoscopy AI

AI Medical Services announced today that it has raised JPY 8 billion in a Series C round of financing with SoftBank Vision Fund 2 as lead investor and participation from existing investors Globis Capital Partners, WiL, LLC. and Incubate Fund. SoftBank Vision Fund is one of the world's largest technology funds investing in AI-related companies, with cumulative investments of $129.6 billion¹ from inception through the end of 2021. With this financing, AIM will deploy its AI-based endoscopic diagnostic support system globally and accelerate the construction of a cloud platform for endoscopic AI.

 What is AIM's mission?

About 30% of all annual cancer patient deaths are due to cancers of the digestive tract. This figure is the highest in Japan and the world. Most cancers are curable if detected early, but if detected late, they can be fatal.Endoscopy is the only test that can definitively diagnose cancer of the digestive tract at an early stageBy utilizing AI, AIM aims to save lives of patients around the world by improving testing accuracy and promoting early detection of cancer.

Japan's Position in Endoscopic Medicine

In endoscopic medicine, Japan is the birthplace and world leader. Therefore, the data accumulated in Japan is among the highest in the world in terms of both quality and quantity. Therefore,The endoscopic AI developed with the wisdom of Japanese endoscopists has the potential to compete well in the global market.

Collaboration with SoftBank Group

With this financing, AIM, with the cooperation of the SoftBank Group, will deploy endoscopic AI, which is the culmination of the wisdom of Japanese endoscopists, around the world. For the future, AIM intends to deploy the endoscopic AI initially on-premise, and in the future, as a cloud platform. If endoscopic AI can be deployed in the cloud, everyone in the world will be able to receive state-of-the-art endoscopic care, which is expected to lead to early detection of cancer and a reduction in deaths.

Global Development of Endoscopic AI

AIM's policy with this financing

1. Accelerate global business
 →Promoting joint research and product development with medical institutions in the U.S., Asia, etc.
 →Æ Acquire talented engineers to promote global expansion.
2. Realization of a cloud platform to eradicate gastrointestinal cancers worldwide
 →Build a platform to link endoscopy laboratories around the world with AI in the cloud.

Kentaro Matsui, Managing Partner, SoftBank Investment Advisers Comments

We greatly share AIM's noble vision of "further advancement of Japan's world-leading endoscopic medicine" and "saving the precious lives of cancer patients around the world. SVF, together with other SoftBank Group companies, hopes to contribute to the acceleration of AIM's growth and global expansion. We look forward to working with the Softbank Group companies to help accelerate AIM's growth and global expansion.

Comments by Yasuyuki Imai, Representative Director, Executive Vice President and COO, SoftBank Corp.

Last year, AIM and AIM jointly conducted a demonstration experiment utilizing 5G². With this investment from SoftBank Vision Fund 2, we hope to further deepen the partnership between the two companies and promote medical DX in Japan. We hope that the collaboration between AIM and SoftBank will bring this vision closer to reality, and that the development of endoscopic medicine will help patients around the world.

Comment from Mr. Satoshi Fukushima, Director, Globis Capital Partners

I am pleased that AIM, led by CEO Tada, will be able to expand from Japan to the world in earnest with stronger supporters, and I will support AIM more than ever with a strong sense of confidence and mission for the future that the world-first technology from Japan, built by AIM, will save many patients' lives on a global scale.

WiL, LLC. Co-Founder and General Partner Masanao Matsumoto Comments

We believe that AIM's use of its technology to solve medical problems and issues that are not confined to Japan will lead to even more advanced development of endoscopic medicine in Japan, a country that leads the world. I am confident that the company's goal of "saving patients around the world" will be realized. We are pleased to be able to support this project again.

Yusuke Murata, General Partner, Incubate Fund Comments

AIM has sounded the gun for global expansion.
I believe it will save the lives of many patients around the world.
We hope that this round will result in a shortening of the timeline for its realization, if only by a little.

Mr. Tomohiro Tada, CEO, AI Medical Service Comments

Japan is the birthplace of gastrointestinal endoscopic medical devices, and Japanese manufacturers account for 98% of the world market share of soft gastrointestinal endoscopes in Japan, Olympus, Fujifilm, and Pentax. The skills of Japanese gastrointestinal endoscopists are among the best in the world, and more than 17 million high-quality endoscopic examinations are performed annually in Japan. Therefore, Japanese endoscopic AI is a new global innovation created from world-class teacher data in both mass and quality.

We have conducted joint research with more than 100 top medical institutions in Japan, including Cancer Institute Hospital Ariake, and have published dozens of world-first papers, including the world's first successful research and development of AI for Pylori gastritis identification, gastric cancer detection, and esophageal cancer detection, making us a world leader in endoscopic AI research and development. We believe that if endoscopic AI, an innovation originating in Japan, can be developed globally with the support of SOFTBANK, it will contribute to the development of endoscopic medicine worldwide and will significantly increase the number of cancers detected in their early stages, saving the lives of many patients around the world. This large-scale procurement has allowed us to raise the stage of our activities to the global level. We will continue to make progress and continuous improvement and spread our wings to the world.

About AI Medical Services

AIM is a medical AI startup company established with the mission of "Saving the world's patients - to achieve zero missed cancer cases with endoscopic AI". Japan is at the forefront of endoscopic medicine, and has accumulated the world's highest quality and quantity of data. Among them, AIM is conducting joint research and product development with more than 100 medical facilities, and AIM aims to reduce the number of missed cancer cases and save patients around the world by bringing endoscopic AI to the medical field as quickly as possible.

name of companyAI Medical Service Co.
EstablishmentSeptember 1, 2017
Location11F HarezaTower, 1-18-1 Higashi-Ikebukuro, Toshima-ku, Tokyo 170-0013, Japan
representativeTomohiro Tada
Business OverviewDevelopment of AI (Artificial Intelligence) to support diagnostic imaging of endoscopes
uniform resouce locatorhttps://ai-ms.com/

comment
¹ Cumulative investment in SVF1 and SVF2 from inception to December 2021
(Adapted from SoftBank Group Corp. investor presentation material for the third quarter of the fiscal year ending March 31, 2022)
²Related Press Release: 5G Demonstration of Endoscopy AI https://www.ai-ms.com/20210326/468/

PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。